The concern over increased intravascular volume and associated anemia, edema, and chronic heart failure in this patient population is not warranted. A possible reason for this is that any increase in intravascular volume will be removed by hemodialysis. We conclude that thiazolidinediones, specifically rosiglitazone and pioglitazone, are safe and effective for ambulatory patients receiving hemodialysis. However, we found that these drugs reduced systolic and diastolic blood pressure in these patients, which warrants further investigation.
Address reprint requests to Harold J. Manley, Pharm.D., BCPS, University of Missouri-Kansas City, 2411 Holmes Street, M3-C19, Kansas City, MO 64108; e-mail: ManleyH @UMKC.edu.
Pharmacotherapy. 2003;23(7) © 2003 Pharmacotherapy Publications
Copyright © 1999, Pharmacotherapy Publications, Inc., All rights reserved.
Cite this: Thiazolidinedione Safety and Efficacy in Ambulatory Patients Receiving Hemodialysis - Medscape - Jul 01, 2003.